The Significance of Sodium Balance and the Value of Salt-blood Test in Identifying Salt Sensitive Patients (VASA)
The Significance of Sodium Balance for Blood Pressure in Patients With Essential Hypertension and the Value of Salt-blood Test in Identifying Salt Sensitive Patients With Hypertension
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Camilla Lundgreen Duus, MD
- Phone Number: +45 78436580
- Email: camduu@rm.dk
Study Locations
-
-
-
Herning, Denmark, 7400
- University Clinic in Nephrology and Hypertension
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- BMI ≤ 35 kg/m2
- Essential hypertension
- eGFR > 15 ml/min/1,73m2
- Albumine-to-creatinine-ratio < 500 mg/g
- Safe anticonception if women in childbearing age.
- Able to adhere to dietary regimen
Exclusion Criteria:
- Secondary hypertension
- Clinically significant heart failure (NYHA 3-4)
- Clinically significant liver disease
- Diabetes mellitus (type 1 and 2)
- Active cancer (except skin cancer)
- Renal transplant
- Recent stroke, transcient ischemic attack or myocardial infarction (within 6 months)
- Proliferative glomerulonephritis or ANCA-related disease
- Continuous immunosuppressant treatment
- Pregnancy or lactation
- Alcohol abuse
- If the investigator finds the participant unfit to complete the project
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Sodium restriction
|
Participants will be guided in minimizing sodium intake.
Guidance will be both oral and written.
Bread with low sodium content will be offered to the participants.
|
|
No Intervention: Usual diet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in systolic 24-hour blood pressure
Time Frame: Measured before and after 4 weeks' intervention
|
Difference in systolic blood pressure measured before and after intervention
|
Measured before and after 4 weeks' intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Camilla Lundgreen Duus, University Clinic in Nephrology and Hypertension
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CLD-2-2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.